The antiarrhythmic effects of a new calcium channel blocking agent (SD-3211) and its stereoisomer with additional sodium channel blocking activity (SA3212), were compared with those of a known antiarrhythmic drug (bepridil), using the left coronary artery ligation-and reperfusion-associated arrhythmia models both in isolated rat hearts and in anaesthetized rats.
Summary.
The antiarrhythmic effects of a new calcium channel blocking agent (SD-3211) and its stereoisomer with additional sodium channel blocking activity (SA3212), were compared with those of a known antiarrhythmic drug (bepridil), using the left coronary artery ligation-and reperfusion-associated arrhythmia models both in isolated rat hearts and in anaesthetized rats.
Isolated and perfused rat hearts were subjected to regional ischaemia for 15 min and subsequent reperfusion for 5 min. SD-321 ] and SA3212 showed dose-dependently prolongations of the time interval between coronary ligation and first appearance of ventricular premature beats, reductions in the number of total ventricular premature beats during the ligation period and reductions in the incidence of reperfusion-induced ventricular fibrillation. The values of the negative logarithm of ICso (mol/1) of SD-3211, SA3212 and bepridil were 7.97, 7.41 and 6.64 for the reduction of ventricular premature beats during ligation and 6.43, 7.49 and 6.17 for the reduction ofventricular fibrillation during reperfusion, respectively. In a separate study on force of concentration and coronary flow in perfused heart paced at 340-360 beats/min SD-3211 caused a significant negative inotropic effect between 10 -7 and 10 -6 mol/1. SA3212 at the concentration of < ]0 -6 mol/1 did not result in any significant change in force of contraction. The coronary flow was increased dose-dependently by SA3212, while it was first increased and then reduced in the presence of higher concentration of SD-3211 (> 10 -v mol/1). Hearts of aneasthetized rats were also subjected to regional ischaemia for 7 min and subsequent reperfusion. SD-3211, even at the lowest dose tested (25 mg/kg), had a marked protective effect against the ligation-associated arrhythmias. The highest dosage of SA3212 tested (100 mg/kg) also reduced them. SA3212, even at the lowest dosage (25 mg/kg), resulted in a significant reduction of the incidence of reperfusion-induced ventricular fibrillation, while only the highest dosage of SD-3211 (100 rag/ kg) reduced it. As for the protective effect against ligaSend offprint requests to M. Fukuchi at the above address tion-associated ventricular premature beats SD-3211 is about seven times as potent as bepridil, and for the reduction in the incidence of reperfusion-induced ventricular fibrillation SA3212 is about fourteen times as potent as bepridil. Significant falls in systolic blood pressure and heart rate were observed at the higher doses of SD-3211 (50 and 100 mg/kg).
Thus, SD-3211 affords substantial protection against ischaemia-induced ventricular antiarrhythmias partly through the negative inotropic and chronotropic effects, and reduction of afterload. The antiarrhythmic action of SA3212 against reperfusion-induced ventricular fibrillation may be partly explained by depression of automaticity together with a reduction of the inward sodium current.
Introduction
The mechanism(s) underlying the genesis of ischaemiaand reperfusion-induced arrhythmias are complex and controversial Corr and Witkowski 1983) . A number of factors have been implicated including stimulation of alpha-and beta-adrenoceptors (Corblan et al. 1976; Sheridan et al. 1980; Kimura et al. 1984) , the elevation of cyclic AMP (Podzuweit et al. 1978) , the formation oflysophosphatides (Corr and Sobel 1982) , the utilization of fatty acids (Kurien et al. 1971; Most et al. 1977) , the activity of the arachidonic acid pathway (Coker et al. 1982) , disturbances of ionic homeostasis, particularly that of calcium and potassium (Opie and Coetzee 1987; Gettes 1987) , the formation of cytotoxic oxygen-derived free radicals (Woodward and Zakaria 1985; Bernier et al. 1986; and the heterogeneity of tissue injury during ) and so forth.
Throughout the last decade a number of reports have suggested that calcium antagonists may be beneficial in preventing the life-threatening ventricular arrhythmias that arise as a consequence of coronary artery occlusion. There have been studies assessing the potentially beneficial effects of nifedipine (Lubbe et al. 1983; Thandroven 1982) , verapamil (Elharrar et al. 1977; Fagbemi et al. 1984) and diltiazem (Anastasiou-Nana et al. 1984; Clusin et al. 1982) .
The antiarrhythmic effects of sodium channel-blocking agents are also well established. Flecainide has been shown to succesffully suppress supraventricular and ventricular arrhythmias in experimental and clinical studies (Somberg and Tepper 1986) . Lidocaine and quinidine are also effective in reperfusion-induced arrhythmia (Uematsuet al. 1986a; Vozeh et al. 1987) .
S D-3211 ((+)-3,4-Dihydro -2- -phenoxy]ethyl]amino]propoxy]phenyl] -4-methyl -3 -oxo -2H -1,4 -benzothiazine hydrogen fumarate) is a new calcium channel blocking agent and, interestingly enough, its stereoisomer SA3212 has properties of sodium channel blocking agents in addition to that as calcium antagonist (see Fig. 1 ). In our preliminary experiments using superfused papillary muscles from guinea pig hearts and the electrophysiological technique with conventional glass microelectrode, SA3212 decreased the maximum upstroke velocity of action potential (Vm,x) (Miyawaki et al., in press ). In the group given SD-3211, the change of ~'m,x expressed as percent change from the control group were 3.4 _+ 1.0% (10 -6 mol/1) and 1.0 _+ 2.4% (10 -5 mol/1), while in the group given SA3212, they were -1.8 + 1.9% (10-6 tool/ 1) and -21.6 + 1.5% (10 5 tool/l). The present study describes the antiarrhythmic effects of SD-3211 and SA3212 as compared with those of bepridil, a recently developed arylalkylamine type of calcium antagonist, which has a sodium channel blocking activity as well.
Materials and methods
In vitro experiments. Male rats of the Sprague-Dawley strain weighing 250-300 g were injected heparin (200 IU, i.p.) 30 min before the experiment. Rats were anaesthetized by i.p. injection of 60 mg/kg pentobarbital sodium and killed by exsanguination. The heart was excised immediately, immersed in ice-cold Krebs-Henseleit buffer and mounted on a Langendorff's apparatus. The perfusate used was oxygenated Krebs-Henseleit solution, with the following composition (mmol/1): NaC1 118, NaHCO3 25, KC1 5.6, MgSO4, 1.18, CaC12 2.52, NaH2PO4 1.28, and glucose 5.55. The perfusion fluid was filtrated through a cellulose acetate membrane (pore size 5.0 I.tm) before it was used, gassed with a mixture of 95% 02 and 5% CO2 and maintained at 37 ° C and pH 7.4. The perfusion pressure was held at a constant value of 100 cm H20. These conditions were constant throughout the experiments. Hearts (n = 6 in each group) were allowed to equilibrate for 20 rain. Then, a solution containing the substance at a certain concentration was perfused for 10 min prior to coronary artery ligation and continued during the subsequent period of ischaemia and reperfusion. A 5-0 atraumatic suture was placed around the left coronary artery. The ligeation of coronary artery was performed by tightening this thread over a short length of light-weight polyethylene tube (1.8 mm OD). One side of the tube had been cut through previously, so as to provide a guide for the tip of a surgical blade as previously described by Selye et al. (1960) and, more recently, by Clark et al. (1980) . The artery was ligated for 15 rain, followed by 5 min of reperfusion according to the method by Lubbe et al. (1978) . The bipolar electrocardiogram (ECG) between the base and apex of the heart was monitored continuously on an ink-writing oscillograph (RECTICORDER, Nihon Kohden, Tokyo, Japan). Heart rate and coronary flow were recorded at 5 min intervals throughout all experiments. The number ofventricular premature beats (VPBs) during the period of coronary ligation were counted. The incidence of ventricular fibrillation (VF), defined as a total irregularity of morphology of the repetitive rapid ventricular beats (Fagbemi et al. 1984) , was also noted.
In a separate series of experiments force of cardiac contraction was measured as maximum upstroke rate of intraventricular pressure (dp/dtm,x) through a catheter inserted from the left atrium into the left ventricle and connected to a pressure transducer and a carrier amplifier (MPU EQ-601G and AP-620G, Nihon Kohden, Tokyo, Japan). Two stainless steel electrodes were placed on the right atrium and the heart was paced at a constant rate of 340 to 360 beats/ min using a stimulator (pulse width: 2 ms; voltage: 2-4 V). The perfusate was weighed continuously to measure coronary outflow (ml/min). Hearts (n = 6 in each group) were allowed to stabilized for 25 min, before changing to a solution containing the substance, the concentration of which was increased in a cumulative way every 15 min.
SD-3211 together with SA3212 and bepridil were obtained as powder. Structural formulas are shown in Fig. 1 . All reagents used were of the highest analytical grade available. Stock solutions of drug were prepared at 10 mmol/1 in 100% DMSO (dimethyl snlfoxide) and diluted further with Krebs-Henseleit solution. Final DMSO concentrations never exceeded 0.3% and did not signifi- 4/10 9/10 10/10 10/10 100 7/10 6/10 5/10 7/10 7/10 8/10 300 7/10 6/10 3/10 6/10 6/10 7/10
Each agent in 3% arabic gum was administered orally to rats in conscious state 90 rain (for bepridil) or 120 rain (for SD-3211 and SA3212) before the coronary artery ligation. Control rates received only the solvent in the largest volume administered to rats in the drug-treated groups. The coronary occlusion was maintained for 7 rain. Each heart was then reperfused for 15 rain. The incidence of ventricularpremature beats (VPBs), ventricular tachycardia (VT) and ventricular fibrillation (VF) is given in parentheses as the number of hearts which showed the respective arrhythmia/the number of hearts observed. *P < 0.05; **P < 0.01 compared with control group cantly affect the results. Only DMSO in a concentration corresponding to the test solution was added to the perfusate for the controls.
In vivo experiments. Male Sprague-Dawley rats, weighing 250-300 g, were used for this study. Ten animals were studied in each group. Aneasthesia was induced with pentobarbital sodium (60 rag/ kg, i.p.), with small additional amounts administered intravenously as required. The left femoral artery was cannulated for measuring the arterial pressure through a pressure transducer and a carrier amplifier (MPU EQ-601G and AP-620G, Nihon Kohden, Tokyo, Japan). The trachea was cannulated for artificial respiration. Positive pressure artificial respiration was started immediately with room air with the use of a stroke volume of approximately 20 ml/ kg and at a rate of 55 strokes/min. The ECG was recorded via standard limb leads together with arterial pressure on an ink-writing oscillograph (RJG-3014, Nihon Kohden, Tokyo, Japan). Body temperature was maintained with a heated operating platform and heating lamps. The chest was opened by left thoracotomy at the fifth intercostal space. After opening the pericardium a 5-0 atraumatic suture was placed around the left coronary artery. The coronary ligation was perforemd in the same way as in the in vitro experiment. After 7 rain ligation, the coronary artery was reperfused by cutting the ligature. The incidences of VPBs, of ventricular tachycardia (VT: defined as seven or more consecutive ventricular ectopic beats) and of VF was monitored (Clark et al. 1980; Kane et al. 1984) . Each of SD-3211, SA3212 or bepridil was dissolved in arabic gum (3%) and administered orally 120 rain (SD-3211 and SA3212) or 90 rain (bepridil) before coronary artery ligation, because T .... of SD-3211 and SA3212 is 120 min and that of bepridil is 90 rain (unpublished data). Solutions were prepared freshly in the dark each day and kept protected from light. Control rats received only the solvent in the largest volume administered to rats in the drug-treated groups.
Statistical evaluation. All data are presented as arithmetric means _+ SEM. A one-way analysis of variance was first performed to test for any differences between the mean values of all groups. If a difference was established, each of the treated groups was compared with the control group, using Dunnett's test. The concentration needed for each drug to suppress VPBs completely during ligation and the incidence of VF by 50% in vitro was obtained by analyzing the data with employment of the Hill's equation and the non-linear least square method (ELSFIT) as reported (Uematsu et al. 1986a; Vozeh et al. 1987) . For the calculation of 50% effectife doses (EDso) in vivo a parallel line analysis was employed.
An analogous procedure was followed for distributions of binominally distributed variables (e. g., incidence of VF). An overall chi-square test for a 2 x n table was constructed, followed by a sequence of Fisher's exact test to compare individual groups.
Drugs used in this study. SD-3211 and SA3212 were obtained from Santen Pharmaceutical Co., Ltd. Bepridil was obtained from Nippon Organon K. K.
Results

Effects on heart rate and coronary JTow in vitro
The effects of various concentrations of SD-3211, SA3212 and bepridil on coronary flow and heart rate, which were evaluated just before the coronary ligation, are depicted in Fig. 2 . In the group given SD-3211, concentrationdependent increases of coronary flow were observed in lower concentrations (Fig. 2, top) . Maximal increase of coronary flow was shown at 10 .8 tool/1 (14.4 _+ 0.4 ml • rain-1, g 1) when coronary flow in the control drugfree hearts was 12.5 _+ 0.5 ml • rain-1. g-i. The higher concentrations of SD-3211 significantly suppressed the increase in coronary flow with 12.7 -t-0.4 ml. rain-1. g-1 at 10 6 tool/1 when the control group was 11.9_+0.8 ml • rain -1 • g-i. SA3212 showed dose-dependent increases of coronary flow. Maximal increase of coronary flow was observed at 3x 10 -6 tool/1 (14.6 + 0.1 ml • rain-1 .g 1) when the control group was 12.0-t-0.4 
. Effects of SD-3211 (open circles), SA3212 (filled circles) and bepridil (filled triangles) on coronary flow and heart rates in
Langendorff-perfused rat hearts. The changes of coronary flow are expressed as the absolute change (ml • rain 1. g 1) from the basal level. The coronary flows in the control state were not significantly different among the groups. Each data point represents the mean _+ SEM of 6 hearts *P < 0.05; **P < 0.01 ml • min-a • g-~. Bepridil also showed dose-dependent increases of coronary flow except at 10-5 mol/1. Maximal increase of coronary flow was obtained at 3 x ]0 .6 tool/1 (14.4 _+ 0.9 ml -min-1 . g-1) when the control group was 11.9 -t-0.7 ml • min-~ -g-~. Administration of the drug did not result in any significant change in heart rate except SD-3211 (]0 -6 mol/1) and bepridil (10 -5 mol/1) gave rise to atrioventricular block (Fig. 2, bottom) . Heart rate in the control group was 336 _+ 18 beats/rain. In the group given SD-3211, heart rate was 34] _+ ] ] beats/rain (10 -9 tool/l) and 376 -t-9 beats/min (3 x 10 -7 mol/1). In the group given SA3212, heart rate was 329 _+ 10 beats/ min (10 -9 mol/1) and 363 _+ 5 beats/min (3 x 10 -6 mol/1). In the group given bepridil, heart rate was 322 ___ 12 beats/ min (10 -8 mol/1) and 344 _+ 8 beats/min (3 x 10 .6 mol/1).
Effects on ligation arrhythmias in vitro
The effects of SD-3211, SA3212 and bepridil on arrhythmias induced by coronary artery ligation are shown in Fig 3 . In control hearts, the time required to initiate VPB (initiation time) was 372.8 -t-29 s and the total number of VPBs was 66.5 _ 13 beats. Five out of six hearts in the control group had VT without occurrence of VF during the ligation period. In durg-treated hearts, VT and VF never occurred during the ligation period. SD-3211, SA3212 and bepridil showed dose-dependent prolonga- 
Fig. 3. Effects of SD-3211 (open circles), SA3212 (filled circles) and bepridil (filled triangles) on coronary artery ligation-associated ar-
rhythmias in perfused rat hearts. The time needed for the first appearance of ventricular premature beats after coronary ligation is expressed as initiation time and the total number of ventricular permature beats during the ligation is also shown. Each data point represents the mean ± SEM of 6 hearts. In 5 out of 6 hearts given 10 -6 mol/1 of SA3212, in 2 out of 6 hearts given 10 -6 mol/l of bepridil and in 3 out of hearts given 3 x 10 6 tool/1 of bepridil, no ventricular premature beat occurred during the regional ischaemia of 15 min duration. *P < 0.05; *P < 0.01 tions of the initiation time for VPBs (Fig. 3, top) . The longest values for prolonging initiation time was 767.4 s (SD-32]1 : 3 x 10 -v mol/1), 716.2 s (SA3212:10 .6 mol/1) and 638.5 s (bepridil: 3 x ]0 -6 tool/l). A dose-dependent reduction of the total number of VPBs during the ligation was also observed for each of the three drugs (Fig. 3,  bottom) . In 5 out of 6 hearts given 10 6 mol/1 of SA3212, in 2 out of 6 hearts given ]0 -6 tool/1 bepridil and in 3 out of 6 hearts given 3 x 10 -6 tool/1 bepridil, no VPBs occurred during the ligation. At 3 x 10 6 mol/1 os SA3212 a complete suppression of VPB was achieved. The negative logarithm of IC5o for SD-3211, SA3212 and bepridil was 7.97, 7.41 and 6.64. Figure 4 shows the incidence of reperfusion-induced VF in drug-treated groups. In the control group, all hearts (n = 6) exhibited VF immediately after the reperfusion. SD-3211 (]0-6mol/1) and SA3212 (10-6mol/1 and 3 x 10 -6 mol/1 completely suppressed the occurrence of VF during reperfusion. 
Studies of reperfusion arrhythmias in vitro
Effects on force of contraction and coronary flow in paced hearts in vitro
The lower concentrations of SD-3211, SA3212 and bepridil (< 10 -s tool/l) did not result in any significant change in force of contraction in paced hearts (Fig. 5,  top) . SD-3211 at the concentration range of 10 -7 mol/l and 10 6 mol/1 caused a significant negative inotropic effect as expected for a typical calcium entry blocker. In the group given SD-3211, dp/dtmax was 1985 -t-56 mm Hg/s (10 -7 tool/l) 1715 _+ 65 mmHg/s (10 -6 tool/l) as compared to 2450 + 34 mmHg/s in the control group. The highest concentrations tested of SA3212 and bepridil ( 1 0 -6 mol/1) also showed a significant negative inotropic effect. In the group given SA3212, dp/dtmax was 1974 _+48mmHg/s (10-6mol/1) as compared to 2467 __ 21 mmHg/s in the control group. In the group given bepridil, dp/dtm,x was 2048 _+ 67 mmHg/s (10-6 tool/l) as compared to 2467 _+ 21 mmHg/s in the control group. SD-3211, SA3212 and bepridil caused significant changes in coronary flow (Fig. 5, bottom) . The higher concentrations ofSD-3211 (> 10-7 mol/1) reduced the coronary flow. At the highest concentration of SA3212 (10 -6 tool/ 1), coronary flow was 9.6 -t-0.3 ml/min as compared to 10.3-t-0.4ml/min in the control group. SD-3211 and bepridil increased coronary flow as compared to the controls. Table I summarizes the incidence of arrhythmias associated with the coronary artery ligation and reperfusion in the control and drug-treated rats. Although 4 of 10 hearts in the control animals fibrillated, mortality was null since spontaneous reversion to sinus rhythm always occurred. SD-3211, even at the lowest dosage (25 mg/kg) had a marked protective effect against ligation-induced arrhythmias. The highest dosage of SA3212 (100 mg/kg) also reduced this kind of arrhythmias. In the control of contraction and coronary flow in perfused rat hearts, which were paced throughout the experiment. Each data point represents the mean _+ SEM of 6 hearts. The changes in force of contraction are expressed as percent from the initial value of force after 25 min for stabilization. The force of contraction measured as maximum upstroke rate ofintraventricular pressure in the control state was not significantly different among the four groups (2467 + 21 mmHg/s in the group of vehicle, 2450 _+ 34 mmHg/s in the group ofSD-3211, 2467 _+ 21 mmHg/s in the group of SA3212, 2467 _+ 21 mmHg/s in the group of bepridil). The changes of coronary flow are expressed as the absolute change (ml/min) from the basal level. The coronary flows in the control state were not significantly different among the four groups (11.6 _+ 0.2 ml/min in the control group, 11.8 _+ 0.5 ml/ rain in the group of SD-3211, 11.5 _+ 0.2 ml/min in the group of SA3212 and 11.7 + 0.3 ml/min in the group of bepridil). *P < 0.05; **P < 0.01 group, 10 of 10 animals exhibited VF immediately after the intervention for reperfusion. SA3212, even at the lowest dosage (25 mg/kg), resulted in a dramatic reduction in the incidence of reperfusion-induced VF. The highest dosage of SD-3211 (100 mg/kg) also reduced reperfusion-induced VF. On the other hand, within the range of bepridil dosage employed in this study the incidence of arrhythmias was identical to that of the control group. Table 2 shows the haemodynamic variables measured just before the period of coronary occlusion. In the lowest dosage used, SA3212 and bepridil did not significantly alter either arterial blood pressure or heart rate. At the lowest dosage (25 mg/kg), SD-3211 tended to decrease systolic blood pressure and heart rate. A fall in systolic blood pressure and heart rate was apparent at the higher dosages of SD-3211 (50 and 100 mg/kg). The Values are expressed as means ± SEM; n = 10 rats in each group. SBP: systolic blood pressure; DBP; diastolic blood pressure; HR: heart rate. *P < 0.05; **P < 0.01 compared with control group highest dosage of bepridil (300 mg/kg) also decreased systolic blood pressure.
Studies of antiarrhythmic and haemodynamic effects in vivo
Discussion
This study shows that antiarrhythmic effects of SD-3211 and SA3212 can be well demonstrated in the arrhythmias following the interventions of coronary artery ligation and reperfusion, both in anaesthesized rats and in the isolated rat hearts. Table 3 summarizes -logICso and EDso values of SD-3211, SA3212 and bepridil for suppressing the total number of ligation-induced VPBs and the incidence of reperfusion-induced VF.
In protective effects against ligation-induced arrhythmias a new calcium channel blocking agent, SD-3211 is about twenty-one times as effective as bepridil in vitro and about seven times in vivo. Since the initial report by Kaumann and Aramendia (1968) which described the protective effect of verapamil against ventricular fibrillation in the dog with coronary occlusion, there have been many studies which have attributed antiarrhythmic properties to calcium antagonists (Thandroyen 1983; Peter et al. 1983) . Recently, Curtis et al. (1984) demonstrated the dose-dependent ability ofverapamil to protect the heart against severe ventricular arrhythmias during early myocardial ischaemia. These authors concluded that the antiarrhythmic actions of the drug were mainly due to its inhibitory effects on calcium movements. The present study demonstrated the ability of another calcium antagonist, SD-3211, to prevent ischaemia-induced arrhythmias in a very similar preparation.
In protective effects against ligation-induced arrhythmias a sodium channel blocking agent with a property of calcium antagonist as well, SA3212, is about six times as effective as bepridil in vitro and about three times in vivo. It has been suggested by Opie et al. (1984) and Thandroyen (1982) that the ability of calcium antagonists to protect against ischaemia-induced arrhythmias is due Relative potencies of SD-3211 and SA3212 to bepridil as a reference drug were depicted in the parentheses. Abbreviations are the same in Table 1 not only to calcium antagonism but also to the other effects such as fast sodium channel inhibition and alphaadrenoceptor blockade. The results of the present study suggests that SD-3211 was more effective than SA3212 against ligation-induced arrhythmias. With regard to the calcium antagonistic action, SD-3211 was found in preliminary experiments to be about four times as potent as SA3212 (data not shown). This would perhaps strengthen the view that, the antiarrhythmic actions during ligation may be mainly due to slow channel inhibition. As for the reduction in incidence of reperfusion-induced VF, SD-3211 is about two times as effective as bepridil in vitro and about six times in vivo. In the isolated rat heart, nifedipine did not appear to reduce the incidence of reperfusion arrhythmias (Hope et al. 1983) . We have also shown that another dihydropyridine-type calcium antagonist failed to show any protective effect against reperfusion-induced arrhythmias because it preferentially acted on coronary vessels and caused the "steal"-phenomenon (Uematsu et al. 1986b) . SD-3211 is a non-dihydropyridine type calcium antagonist and has effects on both blood vessel and cardiac muscle. In addition to its calcium-antagonistic effect it inhibits the fast sodium channel at high concentrations, indicating a beneficial effect against reperfusion-induced VF as shown in this study. As for the reduction in incidence of reperfusion-induced VF, SA3212 is about twenty-one times as effective as bepridil in vitro and about fourteen times in vivo. The antiarrhythmic effect of sodium channelblocking agents are well established. Flecainide is a prototype of class Ic antiarrhythmic drugs which has been shown to successfully suppress supraventricular and ventricular arrhythmias in experimental and clinical studies (for review, see Bigger 1984; Somberg and Tepper 1986) . The sodium channel blocking action of class I antiarrhythmic drugs is believed to be important for their antiarrhythmic activity (Hauswirth and Singh 1979; Grant et al. 1984; Hondeghem and Katzung 1984) . Lidocaine and quinidine are also effective in this reperfusion-induced arrhythmias (Uematsu et al. 1986a; Vozeh et al. 1987 ). SA3212 has also been thought to inhibit both the fast sodium and slow calcium currents and to be effective against reperfusion arrhythmias. The relative potency of the drug against sodium and calcium channels is 4:1 (data not shown). This would perhaps support the view that, at least in the rat, the antiarrhythmic actions of agents such as SD-3211 and SA3212 (and possibly bepridil) during reperfusion may be mainly due not to their slow channel antagonism but to their ability to block the fast inward current. Interestingly enough, the ranges of effective drug concentrations against VF during the coronary reperfusion for SD-3211, SA3212 and bepridil, respectively, were similar during both series of in vitro and in vivo experiments. Although we did not measure serum drug levels, by the oral dosing of 10 rag/ kg of SD-3211 or SA3212 serum drug concentration free from protein binding was calculated to be about 2 x 10 -s mol/1 and by the oral dosing of 5 mg/kg of bepridil it was calculated to be 3 x 10-s tool/1 according to data in the respective preclinical experiments using rats. From these the effective range of drug concentration were suggested to be almost identical for the in vitro and in vivo experiments. The isolated heart preparation has the advantages of a higher reproducibility of arrhythmias, easier control of the drug concentrations, and a shorter time required for the experimental procedure and exclusion of other systemic factors (Uematsu et al. 1986 a) .
